Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Oric Pharmaceuticals has a consensus analyst recommendation of Moderate Buy from 14 firms (11 buys, 2 holds, 1 sell) with an average 12‑month price target of $19.90, well above the recent ~$9.77 share price.
• Institutional investors dominate the cap table, owning about 95.05% of the stock, with recent large stake increases by Vanguard, State Street, OrbiMed and Price T. Rowe and a new position from Paradigm Biocapital.
• CFO Dominic Piscitelli sold 52,000 shares at $13.51 on Feb. 24, reducing his stake by about 43.28% (insiders own 6.82% total), and the company reported a quarterly EPS of -$0.30, beating estimates of -$0.34.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $19.90.

ORIC has been the subject of a number of research reports. Wedbush reduced their target price on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "outperform" rating for the company in a report on Wednesday, April 1st. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. HC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Oric Pharmaceuticals in a report on Thursday, April 2nd. Finally, Citigroup increased their price target on shares of Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th.

Insider Transactions at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 52,000 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the transaction, the chief financial officer directly owned 68,148 shares of the company's stock, valued at $920,679.48. This represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 6.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Oric Pharmaceuticals by 48.8% during the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company's stock worth $55,802,000 after purchasing an additional 1,525,445 shares in the last quarter. State Street Corp raised its holdings in Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company's stock worth $34,834,000 after purchasing an additional 1,854,458 shares in the last quarter. Orbimed Advisors LLC raised its holdings in Oric Pharmaceuticals by 305.0% during the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company's stock worth $43,701,000 after purchasing an additional 2,742,475 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Oric Pharmaceuticals by 14.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company's stock worth $26,955,000 after purchasing an additional 423,795 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new position in Oric Pharmaceuticals during the fourth quarter worth about $19,642,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC opened at $9.77 on Friday. The company has a 50-day simple moving average of $11.26 and a 200-day simple moving average of $11.05. Oric Pharmaceuticals has a one year low of $4.52 and a one year high of $14.93. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -6.43 and a beta of 1.11.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.04. As a group, research analysts forecast that Oric Pharmaceuticals will post -1.34 EPS for the current fiscal year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.